Obesity Correlation With Metastases Development and Response to First-Line Metastatic Chemotherapy in Breast Cancer

Bibliographic Details
Published in:	Clinical Medicine Insights: Oncology
Main Authors:	Mohammed A. Osman, Bryan T. Hennessy
Format:	Article
Language:	English
Published:	SAGE Publishing 2015-11-01
Online Access:	http://www.la-press.com/obesity-correlation-with-metastases-development-and-response-to-first--article-a5221

Similar Items

Extending the duration of first-line chemotherapy in metastatic breast cancer: a perspective review
by: Alessandra Gennari, et al.
Published: (2011-09-01)

Clinical correlation between chemoresponse assay and first line chemotherapy for metastatic colorectal cancer patients
by: Sang Hun Jung, et al.
Published: (2015-12-01)

Biomarkers for evaluating response to chemotherapy in metastatic breast cancer patients
by: Nidhal A.K. Mohammed Ali, et al.
Published: (2017-07-01)

Cost‐Effectiveness Analysis of First‐Line Chemotherapy for Metastatic Pancreatic Cancer in Japan
by: Yuriko Sasahara, et al.
Published: (2025-09-01)

The effectiveness of chemotherapy in breast cancer patients with brain metastases
by: Won Cheol Chang, et al.
Published: (2014-12-01)

Visceral Obesity and a High Glasgow Prognostic Score Are Key Prognostic Factors for Metastatic Colorectal Cancer Treated with First Line Chemotherapy
by: Teppei Kamada, et al.
Published: (2024-10-01)

Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer
by: S Whyte, et al.
Published: (2010-10-01)

Real-world analysis of HER2-ultralow in HR+/HER2– metastatic breast cancer: prevalence and first-line chemotherapy outcomes
by: Laurent Mathiot, et al.
Published: (2025-09-01)

Bevacizumab combined with chemotherapy and anti-PD-1 therapy for the first-line treatment of previously untreated metastatic triple-negative breast cancer
by: Bi-Cheng Wang
Published: (2025-04-01)

Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502
by: Daniel G. Stover, et al.
Published: (2024-08-01)

Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
by: Zhengda Pei, et al.
Published: (2023-10-01)

The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases
by: Amélie Darlix, et al.
Published: (2019-01-01)

RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
by: Jiannan Yao, et al.
Published: (2018-01-01)

Efficacy of Bevacizumab-Capecitabine in Combination for the First-Line Treatment of Metastatic Breast Cancer
by: Stephen Dyar, et al.
Published: (2011-01-01)

Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer
by: Ying-tao Lin, et al.
Published: (2024-01-01)

Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study
by: Boulaamane Lamiaa, et al.
Published: (2012-03-01)

Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program
by: Luc Cabel, et al.
Published: (2021-04-01)

Pharmacoeconomic evaluation of the use of targeted therapy and chemotherapy in the first- and second-line therapies for metastatic colorectal cancer
by: A. A. Tryakin, et al.
Published: (2018-11-01)

ROLE OF PERIOPERATIVE CHEMOTHERAPY IN COMBINED TREATMENT OF METASTATIC COLORECTAL CANCER WITH ISOLATED LUNG OR LIVER METASTASES
by: L. V. Bolotina, et al.
Published: (2015-02-01)

D-dimer as a Predictive Biomarker of Response to Chemotherapy in Patients With Metastatic Breast Cancer
by: Lubana Alkhoder, et al.
Published: (2024-10-01)

Prognostic value of early radiological response to first‐line platinum‐containing chemotherapy in patients with metastatic nasopharyngeal carcinoma
by: Guo‐Ying Liu, et al.
Published: (2020-02-01)

Regional Chemotherapy Is a Valuable Second-Line Approach in Metastatic Esophageal Cancer after Failure to First-Line Palliative Treatment
by: Yogesh Vashist, et al.
Published: (2022-07-01)

Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer
by: Yang Yuan, et al.
Published: (2023-06-01)

Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World Setting
by: Sharman Moser S, et al.
Published: (2024-03-01)

Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer
by: Linda Cucciniello, et al.
Published: (2024-12-01)

Duodenal Obstruction as First Presentation of Metastatic Breast Cancer
by: Sami Khairy, et al.
Published: (2015-01-01)

A liquid biopsy signature of circulating extracellular vesicles-derived RNAs predicts response to first line chemotherapy in patients with metastatic colorectal cancer
by: Ya’nan Yang, et al.
Published: (2023-12-01)

Metabolic reprogramming underlies metastatic potential in an obesity-responsive murine model of metastatic triple negative breast cancer
by: Ciara H. O’Flanagan, et al.
Published: (2017-07-01)

Changes in Water Mobility Measured by Diffusion MRI Predict Response of Metastatic Breast Cancer to Chemotherapy
by: Rebecca J. Theilmann, et al.
Published: (2004-11-01)

Efficacy of pembrolizumab plus lenvatinib as first‐line treatment for metastatic renal cell carcinoma with multiple brain metastases
by: Daisuke Matsumoto, et al.
Published: (2025-01-01)

Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis
by: Maria Rosaria Valerio, et al.
Published: (2021-12-01)

Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience
by: BJ Srinivasa, et al.
Published: (2018-06-01)

Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials
by: Yan-xian Chen, et al.
Published: (2014-01-01)

Cadonilimab plus chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer: a cost-effectiveness analysis
by: Zuojuan Xiang, et al.
Published: (2025-04-01)

Autologous CIK cells combined with chemotherapy as the first-line treatment for locally advanced or metastatic gastric cancer is safe and feasible
by: Xiaoting Ma, et al.
Published: (2023-11-01)

Correlation Between Hemoglobin Levels and the Prognosis of First-Line Chemotherapy in Patients with Advanced Gastric Cancer
by: Wei Q, et al.
Published: (2020-08-01)

Cost-effectiveness analysis of first-line sintilimab plus chemotherapy vs. chemotherapy alone for unresectable advanced or metastatic gastric or gastroesophageal junction cancer in China
by: Zuojuan Xiang, et al.
Published: (2024-09-01)

Cost-effectiveness analysis of FOLFOXIRI/FOLFOXIRI and mFOLFOX6/FOLFIRI treatment in first-line and second-line chemotherapy for metastatic colorectal cancer
by: Jingjing Ma, et al.
Published: (2025-03-01)

Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis
by: Akito Fukuda, et al.
Published: (2022-01-01)

Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice
by: Berta Laquente, et al.
Published: (2020-07-01)